HALLE, Germany--(BUSINESS WIRE)--Scil Proteins, a private biotech company specialized in the discovery, development and production of recombinant proteins, today announced that it has achieved validation of its proprietary Affilin® drug discovery platform in animals. The Company’s lead product, SPVF 2801, an Affilin® molecule for applications in solid tumors passed initial preclinical studies with excellent results.
